Program
irpagratinib
Also written as “ABSK-011 Capsules”, “ABSK-011” and “ABSK-011 180 mg QD combined with atilizumab 1200 mg q3w”.
Its studies are mostly in Carcinoma, Hepatocellular · Liver Neoplasms, led by Abbisko Cayman.
Furthest: phase 2, since Jun 28, 20226 company-led studies, 5 open or runningNext primary completion: Jun 30, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Abbisko Cayman | 65 open or running | phase 2since Jun 28, 2022 | Apr 21, 2021 | Jun 30, 2027phase 2 · NCT07327034 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 21, 2021First study: phase 1 study in Advanced Liver CancerFirst studyNCT04906434 · 200 planned · United States, China, Taiwan
- Jun 28, 2022Phase 2 study in Carcinoma, HepatocellularNCT05441475 · 118 planned · China
- Feb 6, 2024Phase 1 study in Healthy SubjectsNCT06306872 · 40 enrolled · China
- Mar 20, 2025Phase 1 study in Healthy SubjectsNCT06896760 · 6 planned · China
- Nov 26, 2025Phase 2 study in Carcinoma, HepatocellularNCT07327034 · 141 planned · China
- Jul 8, 2026Phase 1 study in Healthy ParticipantsNCT07700953 · 30 planned · China
Ahead
- Jun 30, 2027Primary completion: phase 2 study in Carcinoma, HepatocellularNCT07327034
- Dec 31, 2027Primary completion: phase 1 study in Advanced Liver CancerNCT04906434
- Dec 31, 2028Primary completion: phase 2 study in Carcinoma, HepatocellularNCT05441475
TargetBeta
FGFR4 →read by rule
“An orally bioavailable, selective inhibitor of human fibroblast growth factor receptor 4 (FGFR4), ”NCIt, by rule
Other programs on FGFR4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| infigratinibrule | BridgeBio | phase 3 | 17 |
| futibatinibrule | Otsuka | phase 3 | 10 |
| BB102rule | broadenbio-ltd-co | phase 2 | 2 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07700953Healthy Participants · China | 1 | Recruiting | Aug 10, 2026 | 30 |
| NCT07327034Carcinoma, Hepatocellular · China | 2 | Recruiting | Jun 30, 2027 | 141 |
| NCT06896760Healthy Subjects · China | 1 | Not yet recruiting | Nov 7, 2025 | 6 |
| NCT06306872Healthy Subjects · China | 1 | Completed | Sep 30, 2025 | 40 |
| NCT05441475Carcinoma, Hepatocellular · China | 2 | By invitation | Dec 31, 2028 | 118 |
| NCT04906434Advanced Liver Cancer · United States, China, Taiwan | 1 | Recruiting | Dec 31, 2027 | 200 |
How it is read
Names in the registry
- “ABSK-011 Capsules”, 1 entry
- “ABSK-011”, 1 entry
- “ABSK-011 180 mg QD combined with atilizumab 1200 mg q3w”, 1 entry
- “ABSK-011 200mg BID combined with atilizumab 1200 mg q3w and bevacizumab 15mg/kg”, 1 entry
- “ABSK-011 200mg BID combined with toripalimab 240 mg and bevacizumab biosimilar 15 mg/kg”, 1 entry
Codes read as this program: ABSK011.
Conditions, from the studies’ own filings
- Carcinoma, Hepatocellular, 2 studies
- Liver Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.